UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Zenas BioPharma, Inc. (NASDAQ:ZBIO – Free Report) by 143.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,790 shares of the company’s stock after purchasing an additional 22,267 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.06% of Zenas BioPharma worth $959,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Quarry LP raised its position in shares of Zenas BioPharma by 34.5% during the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after buying an additional 291 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Zenas BioPharma during the third quarter valued at approximately $30,000. Quantbot Technologies LP bought a new stake in Zenas BioPharma during the second quarter worth approximately $49,000. BNP Paribas Financial Markets raised its holdings in Zenas BioPharma by 120.0% during the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after purchasing an additional 1,716 shares in the last quarter. Finally, Sei Investments Co. acquired a new stake in Zenas BioPharma in the second quarter worth approximately $118,000.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on the company. Weiss Ratings cut Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 9th. Citigroup restated a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Wedbush reaffirmed an “outperform” rating and set a $45.00 target price on shares of Zenas BioPharma in a research note on Friday, August 14th. Morgan Stanley lifted their target price on Zenas BioPharma from $22.00 to $32.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Finally, Guggenheim reiterated a “buy” rating and issued a $55.00 price target on shares of Zenas BioPharma in a research report on Friday, August 14th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $45.71.
Zenas BioPharma Trading Up 0.1%
Zenas BioPharma stock opened at $31.12 on Friday. The company has a debt-to-equity ratio of 1.57, a quick ratio of 9.93 and a current ratio of 9.93. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -3.46 and a beta of -1.04. Zenas BioPharma, Inc. has a 1 year low of $13.50 and a 1 year high of $44.60. The firm’s 50 day moving average price is $31.16 and its two-hundred day moving average price is $24.71.
Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The firm had revenue of $1.00 million during the quarter, compared to the consensus estimate of $15.00 million. On average, research analysts predict that Zenas BioPharma, Inc. will post -5.81 EPS for the current fiscal year.
Zenas BioPharma Profile
Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for patients with immune-mediated diseases. The company’s research and development efforts are centered on therapies that modulate the immune system and address conditions with significant unmet medical needs.
Zenas’ lead investigational product is obexelimab, an immune-modulating monoclonal antibody designed to inhibit the activity of certain B cells without broadly depleting them. The company is evaluating obexelimab in autoimmune and inflammatory diseases, including IgG4-related disease and systemic lupus erythematosus.
Featured Articles
- Five stocks we like better than Zenas BioPharma
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Want to see what other hedge funds are holding ZBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zenas BioPharma, Inc. (NASDAQ:ZBIO – Free Report).
Receive News & Ratings for Zenas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
